atogepant: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
atogepant: clinical details
Prescribing considerations
- Confirm whether treatment is intended for an acute attack or prevention, and document migraine pattern and response.
- Review renal and hepatic function and medicines affecting CYP3A4 or OATP transport.
- Warn about constipation, nausea, appetite or weight change, somnolence and potentially delayed hypersensitivity.
- Safety and efficacy have not been established in children.
Contraindications and cautions
- Hypersensitivity to atogepant or any tablet excipient.
- Avoid use in severe hepatic impairment; severe renal impairment or end-stage renal disease requires product review.
Monitoring
- Use a headache diary and functional outcomes to assess preventive benefit.
- Review gastrointestinal effects, appetite, weight and sleepiness.
- Consider liver tests when clinically indicated, including with liver disease or symptoms suggesting hepatic dysfunction.
- Stop and assess promptly if hypersensitivity develops.
Clinical pharmacology
Atogepant is an orally absorbed, selective small-molecule CGRP receptor antagonist. It is metabolised mainly through CYP3A4; renal elimination makes a minor contribution.
Formulation and product differences
- The selected tablet is white to off-white, round and biconvex, debossed “A” and “10”, and is essentially sodium-free.
atogepant preparations and strengths
Tablet
Route: Oral
Strengths: 10 mg, 60 mg
atogepant interactions
The full medicine list should be checked because some enzyme and transporter inhibitors substantially alter atogepant exposure.
Strong CYP3A4 inhibitors, including clarithromycin, itraconazole, ketoconazole, voriconazole and ritonavir
They can markedly increase atogepant exposure, so the prescription requires review.
Strong OATP inhibitors, including ciclosporin, atazanavir, ritonavir, telmisartan and tipranavir
They can increase atogepant exposure and require prescribing review.
Strong or moderate CYP3A4 inducers
They may lower atogepant exposure and potentially reduce its effect.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.